Skip to main content

Table 5 Association between ID4 gene methylation status and MDS subtypes

From: Clinical implications of the quantitative detection of ID4 gene methylation in myelodysplastic syndrome

  Total Methylation level P value Methylated P value
Patients (N) 100    27  
IPSS karyotype 37   0.360 9 0.298
 Good 22 0.14 (0 to 2.72)   4  
 Intermediate 9 0.24 (0 to 0.80)   4  
 Poor 6 0.04 (0 to 0.24)   1  
BM blast (%)    0.098   <0.001
 <5 75 0.47 (0 to 1.51)   10  
 5 to 10 13 0.84 (0 to 3.79)   8  
 11 to 19 12 1.03 (0 to 2.80)   9  
IPSS cytopenias    0.734   0.787
 0/1 22 0.24 (0 to 2.80)   5  
 2/3 78 0.20 (0 to 3.79)   22  
IPSS risk group 35   0.007 9 0.002
 Low-risk (low/int-1) 24 0.03 (0 to 0.76)   2  
 High-risk (Int-2/high) 11 0.43 (0 to 2.72)   7  
WHO subtype 100    27  
Risk    0.000   <0.001
 Low risk 70 0.06 (0 to 1.51)   9  
 High risk 30 0.54 (0 to 3.79)   18  
Subtype    0.000   <0.001
 RA 41 0.04 (0 to 0.59)   4  
 RCMD 22 0.06 (0 to 0.76)   4  
 RARS 7 0.22 (0 to 1.51)   1  
 RAEB-1 21 0.41 (0 to 3.79)   11  
 RAEB-2 9 0.8 (0 to 2.8)   7  
  1. RA, refractory anemia; RARS, refractory anemia with ringed sideroblasts; RCMD, refractory cytopenia with multilineage dysplasia; RCMD-RS, refractory cytopenia with multilineage dysplasia and ringed sideroblasts; RAEB, refractory anemia with excess of blasts; IPSS, International Prognostic Scoring System. Good: normal, −Y, del(5q) or del(20) as the sole abnormality; poor: complex (≥3 abnormalities) or chromosome 7 anomalies.